New combo therapy shows promise for myeloma patients with remaining disease

This study tested whether adding two drugs (ixazomib and dexamethasone) to the standard maintenance drug lenalidomide could better control multiple myeloma that remains after a stem cell transplant. 42 adults who had already started lenalidomide maintenance were randomly assigned to continue lenalidomide alone or switch to the three-drug combination. The goal was to see if the combo could turn more patients' cancer undetectable (MRD-negative) after 12 months.